NCT06494371View on ClinicalTrials.gov

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

August 31, 2028

Conditions
Hodgkin's LymphomaAnaplastic Large Cell Lymphoma
Interventions
BIOLOGICAL

LCAR-HL30 cells

Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

Ruijin Hospital

OTHER